

**DESOXIMETASONE- desoximetasone ointment**  
**E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.**

-----  
**DESOXIMETASONE OINTMENT USP, 0.25%**

FOR EXTERNAL DERMATOLOGIC USE ONLY  
NOT FOR OPHTHALMIC USE.


**Rx only**

**DESCRIPTION**

Desoximetasone Ointment USP, 0.25% contains the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.

Each gram of Desoximetasone Ointment USP, 0.25% contains 2.5 mg of desoximetasone in a base consisting of white petrolatum and medium chain triglycerides.

The chemical name of desoximetasone is: Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-, (11 $\beta$ ,16 $\alpha$ )-. Desoximetasone has the following structural formula:



Molecular Formula: C<sub>22</sub>H<sub>29</sub>FO<sub>4</sub>

Molecular Weight: 376.47

**CLINICAL PHARMACOLOGY**

Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

**Pharmacokinetics:** The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Pharmacokinetic studies in men with Desoximetasone Ointment, USP 0.25% with tagged desoximetasone showed no detectable level (limit of sensitivity: 0.003  $\mu$ g/mL) in 1 subject and 0.004 and 0.006  $\mu$ g/mL in the remaining 2 subjects in the blood when it was applied topically on the back followed by occlusion for 24 hours. The extent of absorption for the ointment was 7% based on radioactivity recovered from urine and feces. Seven days after application, no further radioactivity was

detected in urine or feces. Studies with other similarly structured steroids have shown that predominant metabolite reaction occurs through conjugation to form the glucuronide and sulfate ester.

## **INDICATIONS AND USAGE**

Desoximetasone Ointment, 0.25% is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

## **CONTRAINDICATIONS**

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

## **WARNINGS**

Desoximetasone Ointment 0.25% is not for ophthalmic use.

**Keep out of reach of children.**

## **PRECAUTIONS**

**General:** Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions that augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See **PRECAUTIONS: Pediatric Use**).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatologic infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

**Information for Patients:** Patients using topical corticosteroids should receive the following information and instructions:

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped so as to be occlusive unless directed by the physician.
4. Patients should report any signs of local adverse reactions, especially under occlusive dressing,

to the physician.

5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

**Laboratory Tests:** The following tests may be helpful in evaluating HPA axis suppression:

Urinary free cortisol test

ACTH stimulation test

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of desoximetasone. Desoximetasone was nonmutagenic in the Ames test.

**Pregnancy: Teratogenic Effects–*Pregnancy Category C.*** Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.

Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration in doses 3 to 30 times the human dose of Desoximetasone Ointment, 0.25%.

There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, Desoximetasone Ointment, 0.25% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

**Nursing Mothers:** It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities *not* likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

**Pediatric Use:** *Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.*

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children. Safety and effectiveness of Desoximetasone Ointment, 0.25% in children below the age of 10 have not been established.

## ADVERSE REACTIONS

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

## OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see **PRECAUTIONS**).

## **DOSAGE AND ADMINISTRATION**

Apply a thin film of Desoximetasone Ointment, 0.25% to the affected skin area twice daily. Rub in gently.

## **HOW SUPPLIED**

Desoximetasone Ointment USP, 0.25% is supplied in

15 g tubes NDC 0168-0151-15

60 g tubes NDC 0168-0151-60

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

E. FOUGERA & CO.  
A division of  
FOUGERA  
PHARMACEUTICALS INC.  
Melville, New York 11747

400004A

R09/11

#134

## **PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60 gram TUBE**

**NDC 0168-0151-60**

Fougera®

**DESOXIMETASONE**

**OINTMENT USP 0.25%**

FOR EXTERNAL USE ONLY.

NOT FOR OPHTHALMIC USE.

Rx only

Each gram contains 2.5 mg  
desoximetasone USP in a base  
consisting of white petrolatum and  
medium chain triglycerides.

**NET WT 60 grams**

NDC 0168-0151-60

**fougera**<sup>®</sup>

**DESOXIMETASONE  
OINTMENT USP 0.25%**

FOR EXTERNAL USE ONLY.  
NOT FOR OPHTHALMIC USE.

USUAL DOSAGE: Apply a thin film to the affected skin area twice daily. Rub in gently. See package insert for full prescribing information.  
WARNING: Keep out of reach of children.  
TO OPEN: Use cap to puncture seal.  
IMPORTANT: Do not use if seal has been punctured or is not visible.

E. FOUGERA & CO.  
A division of  
Fougera Pharmaceuticals Inc.  
Melville, New York 11747

**R** only

Each gram contains 2.5 mg desoximetasone USP in a base consisting of white petrolatum and medium chain triglycerides.

**NET WT 60 grams**

Store at 20°-25°C (68°-77°F)  
[see USP Controlled Room Temperature].

See crimp of tube for  
Control No. and Exp. Date.

400002A R09/11



**PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60 gram CARTON**

NDC 0168-0151-60

Fougera<sup>®</sup>

**DESOXIMETASONE  
OINTMENT USP 0.25%**


Rx only

WARNING: Keep out of reach of children.

FOR EXTERNAL USE ONLY.

NOT FOR OPHTHALMIC USE.

**NET WT 60 grams**



## DESOXIMETASONE

desoximetasone ointment

### Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0168-0151
Route of Administration	TOPICAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
desoximetasone (UNII: 4E07GXB7AU) (desoximetasone - UNII:4E07GXB7AU)	desoximetasone	2.5 mg in 1 g

### Inactive Ingredients

Ingredient Name	Strength
petrolatum (UNII: 4T6H12BN9U)	
medium-chain triglycerides (UNII: C9H2L21V7U)	

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0168-0151-15	1 in 1 CARTON	09/28/2012	
1		15 g in 1 TUBE; Type 0: Not a Combination Product		

2	NDC:0168-0151-60	1 in 1 CARTON	09/28/2012	
2		60 g in 1 TUBE; Type 0: Not a Combination Product		
<b>Marketing Information</b>				
<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>		<b>Marketing Start Date</b>	<b>Marketing End Date</b>
ANDA	ANDA078657		09/28/2012	

**Labeler** - E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. (043838424)

Revised: 11/2019

E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.